Tocilizumab
‘Bubbling with new ideas’: Tocilizumab, steroids and the future of GCA treatment
The 2017 FDA approval of tocilizumab as the first drug to specifically treat giant cell arteritis ushered in a new era in the management of the disease, with hopes that it would eliminate the need for steroids in the condition altogether.
Teprotumumab, tocilizumab improve thyroid eye disease symptoms within 24 weeks
Both teprotumumab and tocilizumab reduce inflammation and thyroid eye disease severity, including among adults who were nonresponders to steroid treatment, according to findings published in Thyroid.
Top in rheumatology: Tocilizumab for giant cell arteritis; glucocorticoids for MIS-C
The European Alliance of Associations for Rheumatology issued updated guidance recommending weekly tocilizumab, along with glucocorticoids that should eventually be tapered, for patients with new, relapsing giant cell arteritis.
EULAR: Tocilizumab recommended for new, relapsing giant cell arteritis
Weekly tocilizumab 162 mg is recommended for giant cell arteritis in new or relapsing cases, alongside glucocorticoids that should eventually be tapered, according to an updated EULAR consensus statement on interleukin-6 inhibitors.
IL-6 receptor antagonists, antiplatelets show high probability of benefit for COVID-19
IL-6 receptor antagonists and antiplatelet agents improved chances for 6-month survival among patients with COVID-19, according to study results presented at Society of Critical Care Medicine’s Critical Care Congress and published in JAMA.
Consensus statement on thyroid eye disease focuses on new therapies, individualized care
Individualized care and patient satisfaction are among the areas of emphasis in a new consensus statement on management of thyroid eye disease.
FDA accepts abbreviated BLA for Biogen’s tocilizumab biosimilar
The FDA has accepted an abbreviated biologics license application for a tocilizumab biosimilar candidate, according to a press release from Biogen.
Tocilizumab augments response to remdesivir, dexamethasone in ICU patients with COVID-19
NASHVILLE, Tenn. — Combination therapy with remdesivir and dexamethasone plus tocilizumab yielded reductions in inflammatory markers and mortality and more discharges for patients with COVID-19 hospitalized in the ICU, researchers reported.
FDA grants priority review for tocilizumab to treat patients hospitalized with COVID-19
The FDA has granted priority review for intravenous tocilizumab to treat adults hospitalized with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, mechanical ventilation or extracorporeal membrane oxygenation.
IL-1, IL-6 inhibitors trigger eosinophilia, systemic symptoms in Still's disease subset
A subset of patients with Still’s disease develop drug reactions with eosinophilia and systemic symptoms to interleukin-1 and IL-6 inhibitors, with strong associations among those with common HLA-DRB1*15 haplotypes, according to data.